![]() Therefore, a drug that would prevent this stress in one case could also do the same in the other. SARS-CoV is the coronavirus that caused the SARS outbreak in 2002–2003.Īccording to the investigators, the stress on the endoplasmic reticulum due to SARS-CoV also occurs in infections with SARS-CoV-2. This idea is based on observations about the mechanisms that SARS-CoV triggers. This is a part of the cell where some proteins are modified and moved to other parts of the cell. This is a response that can have fatal effects in severe cases of COVID-19.Īccording to the researchers, 4-PBA may be able to do this by preventing stress on the endoplasmic reticulum. In a study paper that appears in the journal in Cytokine & Growth Factor Reviews, the scientists propose that 4-phenylbutyric acid (4-PBA) - which is a drug for the treatment of urea cycle disorders - may help prevent hyperinflammation. “The escape mutation maps we have generated, as well our methodology for rapidly creating such maps for additional antibodies and sera, should help answer this question,” they add.Ī team from the University of Málaga in Spain and the University of California, Los Angeles has also recently suggested that an existing drug may help prevent excessive inflammation in COVID-19. “The extent to which mutations that substantially affect the antigenicity of SARS-CoV-2 will fix during viral evolution remains an open question,” they write in the study paper. However, being able to predict these mutations could also allow scientists to come up with ways of blocking this mechanism, the study authors argue. ![]() RBD mutations, which can occur over time, could provide SARS-CoV-2 with an escape mechanism that would allow it to avoid detection by the immune system. In the paper, the authors explain how they created a model that allows them to map out all the possible mutations of SARS-CoV-2’s spike receptor-binding domain (RBD), which helps the virus infect healthy cells. Their findings do not yet appear in a peer reviewed journal, but the study paper is available online on the preprint platform bioRxiv. Researchers from various United States institutions - including the University of Washington in Seattle and Vanderbilt University Medical Center in Nashville, TN - are claiming to have drawn “complete escape maps” predicting the various mutations through which SARS-CoV-2 may be able to avoid the detection of antibodies. “We hope our findings can contribute to the amelioration of the COVID-19 pandemic by encouraging further examination of this nanobody as a therapeutic candidate against this viral infection,” says senior study author Prof. These promising initial observations have led the scientists to argue that, subject to future investigation and experiments, the nanobody may eventually help prevent SARS-CoV-2 infection in people at high risk. They say that Ty1 is able to bind strongly to a specific part of the SARS-CoV-2 spike protein, which is what allows the virus to penetrate and infect healthy cells. The researchers zeroed in on Ty1, which is a nanobody that alpacas produce. ![]() ![]() Nanobodies, which amount to around one-tenth of the size of antibodies, can nevertheless be as effective in recognizing markers of foreign agents inside the body. Antigens are structural sequences that are present on infectious agents. In it, they suggest that a nanobody, or an antibody fragment, that alpacas naturally produce could help prevent infection with SARS-CoV-2.Īntibodies are a type of protein that recognize antigens. At the start of September, researchers from Karolinska Institutet in Sweden published a study paper in the journal Nature Communications.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |